Table 3. Initial immunosuppression.
| Regimen, n (%) | death (n = 162) | control (n = 162) |
|---|---|---|
| Induction | ||
| none | 52 (32) | 65 (40) |
| basiliximab | 96 (59) | 80 (49) |
| anti-thymocyte globulin | 14 (9) | 17 (11) |
| Maintenance | ||
| Tacrolimus/mycophenolate | 78 (48) | 68 (42) |
| Tacrolimus/azathioprine | 54 (33) | 56 (35) |
| Tacrolimus/ mTOR inhibitor | 2 (1) | 3 (2) |
| Cyclosporine/mycophenolate | 7 (4) | 6 (4) |
| Cyclosporine/azathioprine | 3 (2) | 13 (8) |
| Cyclosporine/mTOR inhibitor | 5 (3) | 4 (3) |
| Other | 13 (8) | 12 (8) |
mTOR: mammalian target of rapamycin.